TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study in CLL Patients Receiving BR

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of chronic lymphocytic leukemia~* Patients treated with first-line BR for active disease requiring treatment~* Cumulative Illness Rating Scale (CIRS) \> 6~* Informed consent to data collection~Exclusion Criteria:~* Patients treated with BR within prospective clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BR in CLL (Type: None): Patients receive bendamustine hydrochloride 90mg/m2 IV on days 1 and 2 each cycle. Patients also receive rituximab 375 mg/m2 IV on day 1 at first cycle and 500 mg/m2 on day 1 all subsequent cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Microvascular Coronary Disease In Women: Impact Of Ranolazine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women with signs and symptoms of myocardial ischemia (chest pain, abnormal stress testing, abnormal noninvasive testing) in the absence of obstructive coronary artery disease (epicardial coronary stenosis \<50% luminal diameter stenosis).~2. Women with ≥10% myocardial ischemia by CMR perfusion.~Exclusion Criteria:~1. Contraindications to withholding nitrates, beta-blockers, calcium channel agents, ACE/ARB agents for 48 hours prior to testing.~2. Contraindications in CMR including AICD, pacemaker, untreatable claustrophobia or known angio-edema.~3. Contraindications to ranolazine including hepatic insufficiency, prolonged QT, renal failure.~4. Women taking drugs that inhibit CYP3A such as diltiazem, verapamil, ketoconazole, macrolides or HIV protease inhibitors.~5. Women less than 18 years of age.~6. Women on drugs that prolong the QT interval such as Class Ia or III antiarrhythmic agents, erythromycin, certain antipsychotics.~7. Pregnancy or breast feeding.~8. Life expectancy less than 6 months.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Drug Ranexa, Then Placebo (Type: EXPERIMENTAL): Participants first received study drug Ranexa, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.~After a washout period of 2 weeks, they then received Placebo tablet (matching Ranexa tablet).
- Placebo, Then Study Drug Ranexa(Ranolazine) (Type: EXPERIMENTAL): Participants first received Placebo tablet (matching Ranexa tablet) for two weeks.~After washout period of 2 weeks, they then received Ranexa 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of follicular lymphoma: grades I, II, or IIIA, or non-follicular lymphoma: lymphoplasmacytoid lymphoma, small lymphocytic lymphoma, marginal B-cell lymphoma, or MALT lymphoma (as defined in the WHO classification1) as reviewed by a hematopathologist at Memorial Hospital.~* Staging fulfills criteria for no initial treatment according to GELF criteria for advanced stage disease. None of the following should be present:~  * A nodal or extranodal mass with a diameter of \>7 cm,~ * Involvement of at least three nodal sites \[each with a diameter of \>3 cm\],~ * Systemic symptoms,~ * Symptomatic splenomegaly,~ * Ureteral compression.~ * No prior treatment for lymphoma is permitted.~ * Measurable disease is required.~ * Karnofsky performance status \> 70%~ * The patient may not have a previous history of radiation therapy.~ * Patient or guardian must be able to sign voluntary written consent.~ * Male or female patients 18 years of age or greater.~Exclusion Criteria:~* Allergy to biaxin (clarithromycin), erythromycin, or other macrolide antibiotic. Patients requiring use of ergot derivatives, pimozide, cisapride, or astemizole; combination with ranitidine bismuth citrate should not be used in patients with history of acute porphyria or CrCl \<25 mL/minute.~* Prior treatment with Biaxin (clarithromycin) during the prior 6 months.~* Histologic diagnosis of follicular grade 3B or aggressive non-Hodgkin's lymphoma.~* Histologic evidence of transformation from low grade/indolent NHL to aggressive NHL.~* Prior treatment for non-Hodgkin's lymphoma.~* Regional lymphoma (peripheral stages I and II) eligible for involved field irradiation.~* GELF criteria21 for institution of systemic chemotherapy, which includes:~  * A nodal or extranodal mass with a diameter of \>7 cm,~ * Involvement of at least three nodal sites \[each with a diameter of \>3 cm\],~ * Systemic symptoms,~ * Symptomatic splenomegaly,~ * Ureteral compression.~* Patients with a known history of HIV, Hepatitis B or C seropositivity.~* Patients who require therapy with systemic corticosteroids.~* Prior history of malignancy within the past five years or a concurrent malignancy, with the exceptions of cutaneous basal cell carcinoma or carcinoma in situ of the uterine cervix.~* Pregnant or lactating women, since imaging cannot be done in this setting.18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): lymphoma follicular
- 2 (Type: None): lymphoma non-follicular

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* have musculoskeletal pain of the low back, cervical spine, or extremities~* have chronic pain (\>3 months duration)~* have moderate functional impairment~* have access to a working telephone~* Indianapolis Roudebush VA Medical Center patient or Walter Reed Army Medical Center patient~* willing to travel at least once to study site~Exclusion Criteria:~* prior back or cervical spine surgery or surgery pending~* active psychosis~* incompetent for interview~* severe impairment of hearing or speech~* active suicidal ideation~* current alcohol or other substance dependence or abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Study subjects randomized to this arm would receive usual care from their provider(s). No study intervention is undertaken on subjects in this arm. Participants in Usual Care would complete the same four outcome assessments (surveys) throughout the course of the study that members of the intervention complete.
- Stepped Care (Type: EXPERIMENTAL): Study subjects randomized to this arm would receive stepped care for their pain. Stepped care involves FDA-approved analgesic therapy, a 12-week pain self-management program, and if pain does not improve, a 12-week cognitive behavioral therapy program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 1 diabetes for at least one year~* using insulin for at least 1 year~* an insulin pump for at least 6 months~* willingness to switch to lispro (Humalog) or aspart (Novolog) if using glulisine (Apidra).~Exclusion Criteria:~* a medical condition or being been treated with medications that might interfere with the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)~1. SAP=sensor-augmented pump only~2. USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight~3. USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control
- Group B (Type: EXPERIMENTAL): Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP~1. SAP=sensor-augmented pump only~2. USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight~3. USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability of Olodaterol and Fluconazole

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Healthy male and female volunteers

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Olodaterol (Type: EXPERIMENTAL): None
- Olodaterol + Fluconazole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Response Study of Nitisinone in Alkaptonuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria~A subject must fulfil the following criteria in order to be included in the study:~1. Diagnosis of alkaptonuria verified by documented elevated urinary homogentisic acid excretion.~2. Age ≥18 years.~3. Willing and able to visit the investigational site for study visits.~4. Signed written informed consent obtained.~Exclusion criteria~The presence of any of the following will exclude a subject from inclusion in the study:~1. Non-alkaptonuria causes of ochronosis.~2. Currently pregnant or lactating.~3. Known allergy to nitisinone or any of the constituents of the investigational product.~4. Use of a protein-restricted diet~5. Dietary habits or use of homeopathic therapies that interfere with tyrosine catabolism.~6. Current keratopathy, contact lens use or uncontrolled glaucoma.~7. Current malignancy.~8. Uncontrolled hypertension (blood pressure greater than 180 systolic or greater than 95 diastolic).~9. Electrocardiogram changes indicative of myocardial infarction, arrhythmia, tachycardia, bradycardia, left bundle branch block.~10. Chest radiographic abnormalities, including an infiltrative, mass, congestive heart failure, embolism, atelectasis.~11. Serum potassium \< 3.0 mmol/L.~12. eGFR \< 60 mL/min.~13. Any hepatic enzymes greater than 3 x upper limit of normal.~14. Haemoglobin \< 10.0 g/dL.~15. Platelets less than 100 x 109/L.~16. WBC less than 3.0 x 109/L.~17. ESR greater than 100 mm/h.~18. History of alcohol or drug abuse.~19. Participation in another clinical trial within 3 months of randomisation.~20. Treatment with nitisinone within 3 months of randomisation~21. Psychiatric illness or neurological disease that interferes with compliance or communication with health care personnel.~22. Any other medical condition which in the opinion of the investigator makes the subject unsuitable for inclusion.~23. Foreseeable inability to cooperate with given instructions or study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- no treatment (Type: NO_INTERVENTION): comparrator
- Nitisinone 1mg (Type: EXPERIMENTAL): interventional
- Nitisinone 2mg (Type: EXPERIMENTAL): interventional
- Nitisinone 4mg (Type: EXPERIMENTAL): interventional
- Nitisinone 8mg (Type: EXPERIMENTAL): interventional

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Movement Assessment for Concussion Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male football players (2016 and 2017 season)~* Male and female soccer players (2017-2018 and 2018-2019 season) OR Athletes who have been diagnosed with a sports related concussion during the season of their assigned sport and is being seen through concussion clinic at Arkansas children's hospital~  * Age 14-18~ * Written informed consent from the parent~Exclusion Criteria:~* Athletes who have not completed pre-participation physicals~* Any condition that the investigator determines would put the subject at risk if participating in the study.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Healthy athlete (Type: OTHER): Healthy athletes (14-18 years old) enrolled in sports program in local schools.
- Concussed athletes (Type: OTHER): Concussed athletes from a sports related injury who are 14-18 years old and referred to a regional sports concussion clinic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Addition of Zinc to the Current Case Management Package of Diarrhea in a Primary Health Care Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 1 month to 5 years with diarrhea~Exclusion Criteria:~* Illness requiring referral to hospital

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Zinc and ORS were promoted for treatment of diarrhea in underfive children
- 2 (Type: OTHER): Promoted routine management of diarrhea in underfive with ORS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 5-75 years~* Lesions must measure at least 1 cm and be primarily ulcerative~* Have cutaneous leishmaniasis proven parasitologically in the lesion selected for study~* Must have given written informed consent to participate in the study~Exclusion Criteria:~* Known drug intolerance to aminoglycosides in the patient or immediate family~* Previous use of antileishmanial drugs (within 3 months) or present use of routinely nephrotoxic or ototoxic drugs~* Patients with tuberculosis under treatment~* Potential for follow-up: have less than 7 months time remaining in present address and/or plan to leave the area for more than 30 days~* Extent of disease: more than 5 lesions or lesion equal to or greater than 5 cm or a lesion less than 5 cm from the eye, or a lesion in the face that, in the opinion of the attending dermatologist could potentially cause significant disfigurement~* Location of disease: mucosal involvement~* Disseminated disease: clinically significant lymphadenitis with nodules that are painful and greater than 1 cm in size in the lymphatic drainage of the ulcer~* Concomitant medical problems: significant medical problems of the kidney or liver as determined by history and by the following laboratory studies:~* Hearing abnormality~* Ongoing pregnancy or have plans to become pregnant~* Females of child bearing age (Tunisia Only)~* Signs or symptoms of peripheral neuropathy~Kidney: clinically significant abnormalities of urine analysis, serum levels of creatinine, BUN, total proteins greater than the upper limit of normal for the laboratory.~Liver: AST or ALT greater than the upper limit of normal for the laboratory General: glucose, Na+, or K+ greater than the upper limit of normal for the laboratory

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- WR 279,396 (Type: EXPERIMENTAL): WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin
- Placebo (Type: PLACEBO_COMPARATOR): Topical cream vehicle containing all of the components in WR 279,396 except the active ingredients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Cohort Study:~* Weeks of pregnancy between 13 and 22 weeks~* Resident in Mbarara Municipality (radius of 15km from MNRH)~* Cohort study signed informed consent form~Efficacy Study:~* Pregnant woman~* Malaria infection, detected by microscopy, with P. falciparum (mixed or mono-infection)~* Age of gestation: 13 weeks and beyond~* Efficacy study signed informed consent form~Exclusion Criteria:~Efficacy Study:~* P. falciparum parasitaemia above 250,000 parasites/μl~* Severe anaemia~* Signs or symptoms of severe/complicated malaria requiring parenteral treatment (WHO 2000)~* Known allergy to artemisinin derivatives, lumefantrine or quinine;~* Previous participation in the efficacy study~* Inability to attend the efficacy study follow-up schedule.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Quinine (Type: ACTIVE_COMPARATOR): None
- Arthemeter lumefantrine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of metastatic breast cancer~  * No cutaneous metastases on hands or feet~* Pegylated liposomal doxorubicin hydrochloride monotherapy is indicated according to the local investigator~  * Planned dose at least 10 mg/m\^2 per week~* No sign of palmar-plantar erythrodysesthesia (PPE) at study entry~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Able to apply topical medication (cream) or provide for another person to apply cream~* Not pregnant or breastfeeding~* Fertile patients must use effective contraception during trial participation and for 1 month after completion~* Negative pregnancy test~* Compliant and geographically proximal in order to allow proper evaluation and follow-up~* No dermatologic conditions (e.g., psoriasis) that, in the opinion of the physician, may affect the hands or feet or may complicate evaluation during study treatment~* No known allergy or hypersensitivity to F511 cream~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 30 days since prior and no concurrent treatment with other experimental drugs or anticancer therapy~* More than 30 days since prior and no concurrent treatment on another clinical trial~* No concurrent local use of other ointments or creams for hands or feet other than Excipial Repair®

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18-75 will be recruited. All will have an established radiological diagnosis of bronchiectasis (CT of the chest). Patients will have clinically significant bronchiectasis expectorating mucopurulent or purulent sputum when clinically stable with at least 2 chest infections per year.~Exclusion Criteria:~* current smokers or ex-smokers of less than 1 year; \>15 pack year history~* cystic fibrosis~* active allergic bronchopulmonary aspergillosis~* active tuberculosis~* poorly controlled asthma~* pregnancy or breast feeding~* known allergy to statins~* active malignancy~* chronic liver disease~* established cardiovascular or cerebrovascular disease~* statin use in the last year~* patients on long term oral macrolides due to the interaction with statin therapy patients chronically colonised with Pseudomonas aeruginosa (defined as two or more isolates of Pseudomonas aeruginosa whilst clinically stable in 6 months prior to the study).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: ACTIVE_COMPARATOR): Atorvastatin 80mg once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete